Regeneron Pharmaceuticals, Inc. · Healthcare
Survives a bust-sized cut to analyst growth (10 points, or half the forecast if larger), with the median analyst target at least 15% above the price and no more than one earnings-quality red flag.
At a 31.0% margin the price requires -1.0% 3y revenue CAGR against 14.8% consensus, a cushion of +18.1pt versus a 0pt correction cut. Cushion is wide and the drawdown is not the company's own; it should come out ahead of the correction. Unaffected.
Breaks if: Eylea erosion outruns the new launches. We re-check this against analyst estimates every evening.
10 years, at a 31% margin (analysts' margin, cut for cash conversion)
+9.8%/yr over 10 years once faded to terminal growth
points off 3-year analyst growth
23 published targets, set before the drop
Does the profit analysts build their margin on actually arrive as cash? Measured over the last 3 annual statements filed before this test. After stock-based pay, 86% of reported profit arrived as operating cash, so the test cuts the analysts' 39% margin to 33%. That leaves a cushion of +20pt instead of +22pt, and the smaller of the two decides the group.
How much of reported profit arrived as operating cash. Below 0.8× is a red flag.
Profit not backed by cash, as a share of assets, latest year. Above 10% is a red flag.
Staff paid in shares instead of cash, which flatters margins. Above 10% is a red flag.
Dilution of each share's claim on the business. Above 3% a year is a red flag.
Non-operating gains in the latest year. Above 25% is a red flag.
After capex. Shown for context: heavy investment is not bad earnings, so it is never solved under.
From the priced-in reconstruction of Sep 12, 2026. Its figures use that day's price and free-cash-flow margin, so they can differ from the stress test above.
The price sits at the 52nd percentile of 23 published models, almost exactly matching the median target, meaning the market broadly endorses the middle view and explicitly refuses to pay for either the steep bull cases or the deep bear case.
Whether Regeneron can replace declining Eylea sales and the failed Fianlimab melanoma opportunity with its obesity pipeline and other oncology indications, a question that unit volume tracking can partially answer but that ultimately depends on clinical trial readouts no wired dataset can capture.
What the price refuses to pay for, and the full reconstruction, on the REGN quote page →A stress test of whether this narrative is still paid for by analyst forecasts, not a forecast that the stock will rise. The price-implied growth on its own has not predicted returns in our testing, and this list (sealed Nov 21, 2026) has not been graded yet. Cut sizes are assumptions. Not investment advice. Back to all names